L ipoprotein(a) [Lp(a)] is a particle composed of both apolipoprotein [apo](a) and apoB linked by a disulfide bond. Recent studies have demonstrated the importance of genetic variants associated with Lp(a) for risk of coronary artery disease, but the relevance of such variants for stroke and other vascular diseases is uncertain. [1] [2] [3] [4] The Precocious Coronary Artery Disease (PROCARDIS) study identified 2 single-nucleotide polymorphisms (SNPs) at the Lp(a) locus (LPA) on chromosome 6q26 -27 (rs3798220 and rs10455872) that each was strongly and independently related to Lp(a) levels and risk of coronary disease. These 2 SNPs explained about half of the genetic variation in Lp(a) levels at the LPA locus. After adjustment for Lp(a) levels, the effect of the LPA genotype score on risk of coronary disease was completely attenuated, thereby providing strong support for a causal role of Lp(a) levels for coronary disease. 1 
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The relevance of genetic variants at the LPA locus for stroke and other vascular disease outcomes is less certain than for coronary disease. A meta-analysis of prospective observational studies involving Ͼ9000 coronary disease cases and 1900 ischemic strokes demonstrated that the strength of association of Lp(a) with coronary disease risk was similar to that for ischemic stroke [risk ratio, 1.13; 95% CI, 1.09 to 1.18, for coronary disease versus 1.10; 95% CI, 1.02 to 1.18, for ischemic stroke per 1 SD higher usual Lp(a) level after adjustment for cardiovascular risk factors)]. 5 In contrast, LPA variants previously associated with Lp(a) levels that were genotyped in a candidate gene study of 3550 ischemic stroke cases and 6560 controls showed no significant association with ischemic stroke (odds ratio [OR] per allele, 0.96; 95% CI, 0.88 to 1.04, for rs1853021 and 0.95; 95% CI, 0.88 to 1.03, for rs1800769). 6 Furthermore, previous studies examining the associations of Lp(a) concentrations with carotid artery intima-media thickness and flow-mediated arterial dilation failed to demonstrate significant associations. [7] [8] [9] [10] [11] [12] [13] Understanding the effects of Lp(a) at different arterial sites may be informative about the mechanisms by which Lp(a) causes vascular disease and have relevance for potential therapies to lower Lp(a) levels for the prevention of atherothrombotic disease.
The 2 LPA SNPs most strongly related to coronary disease were combined as an LPA genotype score and examined for associations with different vascular outcomes in the Heart Protection Study (HPS), a trial of 40 mg of simvastatin versus placebo in persons at high risk of vascular disease. The aim was to examine the associations of LPA variants with coronary heart disease, stroke, and peripheral vascular disease by first using prevalent cases at enrollment and, secondly, using incident vascular events during an average of 5 years of follow-up.
Methods

Study Population
Details of the HPS have been reported previously. 14, 15 Between 1994 and 1997, 20 536 men and women aged 40 to 80 years were recruited from 69 collaborating hospitals in the United Kingdom (with ethics committee approval). Participants were eligible for inclusion provided that they had nonfasting blood total cholesterol concentrations of at least 135 mg/dL (3.5 mmol/L) and had been given either a previous diagnosis of coronary disease, ischemic stroke, other occlusive disease of noncoronary arteries, diabetes mellitus, or (if men aged Ն65 years) treated hypertension. None of the participants were on statin therapy. At the initial screening visit, all participants provided written consent and began a run-in phase involving 4 weeks of placebo followed by 4 to 6 weeks of 40 mg simvastatin daily, after which compliant and eligible individuals were randomly allocated to 40 mg simvastatin daily or matching placebo for approximately 5 years. A nonfasting blood sample was taken at screening (ie, before starting any statin therapy) and at the end of the run-in (ie, while on 40 mg simvastatin daily).
Participants were to be seen in the study clinics for routine follow-up checks at 4, 8, and 12 months and then every 6 months until the final follow-up visits at a mean of 5 years. Information was recorded at each follow-up of any suspected myocardial infarction, stroke, vascular procedure, cancer, or other serious adverse experience and of the main reasons for all other hospital admissions. Further details were sought from the participants' general practitioners (plus, if considered necessary for coding, from any relevant hospital records) about all reports that might relate to major vascular events, cancers, or deaths and from UK national registries about the sites of any registered cancers and the certified causes of any deaths. All such information was reviewed by coordinating center clinical staff according to prespecified criteria.
For analyses of prevalent disease associations, the cases were individuals who had preexisting coronary heart disease, ischemic stroke, or peripheral vascular disease at the baseline visit. The primary analyses of stroke and of peripheral vascular disease excluded any cases who also had coronary disease. To increase statistical power, 2 sources of controls were used: 2229 controls who had entered the HPS with preexisting diabetes or hypertension but had no history of coronary heart disease, stroke, or peripheral vascular disease and 1458 further controls with no history of myocardial infarction, angina, or other heart disease from the ISIS (International Study of Infarct Survival) who also were recruited in the United Kingdom. 16 For analyses of incident disease associations, the cases were first occurrences during follow-up of coronary heart disease, stroke, or peripheral vascular disease events. Coronary heart disease events included nonfatal myocardial infarction, coronary revascularization, or coronary death. Deaths attributed to myocardial infarction, other coronary disease (including heart failure due to coronary disease), and sudden or unexpected deaths (without postmortem evidence of another cause) were classified as coronary death. Confirmation of myocardial infarction required evidence of either (1) 2 or more of (a) typical symptoms, (b) diagnostic electrocardiographic changes, and (c) diagnostic elevations of cardiac enzyme concentrations or (2) necropsy findings of myocardial infarction that corresponded to symptom onset. ("Silent" myocardial infarctions were not to be included.) Strokes included nonfatal or fatal ischemic, hemorrhagic, or unclassified stroke and were defined as rapid (or uncertain) onset of focal or global neurological deficit lasting Ͼ24 hours or leading to death, with clinical evidence supplemented by neurological imaging or necropsy required to classify strokes as probably ischemic or probably hemorrhagic. (Subarachnoid hemorrhage was to be included, but subdural hematoma or transient cerebral ischemia was not.) Peripheral vascular disease included aortic, carotid, or peripheral revascularization.
Laboratory Assays
The coordinating center laboratory at the Clinical Trial Service Unit in Oxford, England, used standard spectrophotometric enzymatic methods to measure total cholesterol and lipid fractions (including low-density lipoprotein cholesterol [LDL-C] directly) on Beckman autoanalyzers and immunoturbidometric methods to measure apoA 1 and apoB. Extraction of DNA from stored WBCs and genotyping were carried out at the Centre Nationale de Génotypage in Evry, France. Genotyping of 14 481 HPS participants of white ethnic origin was performed with a custom I.PLEX panel. Genotyping of the rs10455872 (A/G) and rs3798220 (T/C) LPA polymorphisms each showed Ͼ99% success rates, with both genotypes available for 14 465 of these HPS participants. ISIS participants were genotyped for the 2 SNPs with the use of a Taqman platform as previously described 1 and showed Ͼ98% success rates. The minor allele frequencies in successfully genotyped HPS participants were 8.9% for rs10455872 (G) and 2.0% for rs3798220 (C), and both SNPs were in Hardy-Weinberg equilibrium (Pϭ0.09 and Pϭ0.22, respectively). The information from the 2 SNPs was combined into a single LPA genotype score, with values corresponding to the sum of the variant alleles (C for rs3798220 and G for rs10455872) in either of the 2 SNPs.
Statistical Analysis
Differences between among characteristics were assessed by ANOVA (for continuous variables) and by 2 test (for categorical variables) and reported as 2-sided P values. ORs per variant allele were estimated using logistic regression for prevalent disease associations, and hazard ratios (HRs) per variant allele were estimated using Cox proportional hazard models for incident disease associations. HR estimates for incident events were adjusted for history of coronary disease (as a 3-way variable coding myocardial infarction, other coronary disease, and no coronary disease); history of ischemic stroke, peripheral vascular disease, and diabetes (as a 5-way variable coding each alone, multiple, and none); and randomized treatment allocation. Sensitivity analyses assuming a dominant effect of the LPA genotype score (1 or more LPA variants versus none) also were performed for both prevalent and incident disease associations. SAS version 9.1 was used for all analyses, and the figures were generated using R version 2.10.1. Table 1 shows selected characteristics at baseline by LPA genotype score. More than 20% of individuals had 1 or more variant alleles, including 1.3% of genotyped individuals who carried 2 variants (and no individuals with Ͼ2 variants were observed). The LPA genotype score was positively associated with age and aspirin use and inversely associated with preexisting diabetes mellitus, although the trend with aspirin use was not consistent. Table 2 shows mean plasma levels of cholesterol fractions and apolipoproteins by LPA genotype score in the statin-free prevalent disease controls. Directly measured LDL-C and the related measure of apoB were weakly positively associated with the LPA score, but again, there was no consistent trend across the score for apoB. The distributions of the LPA genotype score by prevalent and incident disease status are given in online-only Data Supplement Table 1 . Figure 1 shows the associations of the LPA genotype score with prevalent coronary disease, ischemic stroke, and peripheral vascular disease. Individuals with prior coronary disease were excluded when considering LPA associations with ischemic stroke and peripheral vascular disease to control for potential bias. The LPA genotype score was strongly associated with coronary disease (Pϭ0.0002) and, among individuals without known coronary disease, with peripheral vascular disease (Pϭ0.0086), with an Ϸ20% higher risk per additional LPA variant allele for each disease. By contrast, there was no significant association of the LPA score with ischemic stroke (OR, 1.03; 95% CI, 0.89 to 1.20; Pϭ0.67). The effect of the LPA genotype score differed significantly when coronary disease and stroke cases were compared (Pϭ0.04), but not when coronary disease and peripheral vascular disease cases were compared (Pϭ0.93). Sensitivity analyses assuming a dominant model resulted in slightly stronger, but comparable effect sizes, as would be anticipated based on the allele frequencies (online-only Data Supplement Table 2 ). Estimates of the effects of the LPA genotype score in men and women considered separately are given in online-only Data Supplement Table 3 and show no significant interaction of the LPA score with sex in any of the disease groups. Associations of prevalent disease with rs10455872 and rs3798220 genotypes considered separately are provided in online-only Data Supplement Table 4 . The estimated effects of the 2 SNPs had considerably overlapping CIs in each of the disease groups. Furthermore, the individual SNPs provided no statistically significant information over and above the LPA genotype score, suggesting that the LPA score represented all the relevant information (online-only Data Supplement Table 4 ). Overall, among the 2381 participants who had previously had a stroke and the 4896 participants with peripheral vascular disease, 44% and 59%, respectively, also had coronary disease. Online-only Data Supplement Figure 1 shows the associations for stroke and peripheral vascular disease when those with coronary disease were not excluded. The association of the LPA score with ischemic stroke was somewhat increased (OR, 1.09; 95% CI, 0.97 to 1.23; Pϭ0. 14) , and the association with peripheral vascular disease was slightly strengthened (OR, 1.21; 95% CI, 1.09 to 1.33; Pϭ0.0002). Figure 2 shows the associations of the LPA genotype score with incident coronary events, strokes, and peripheral vascu- LPA genotype score is the total number of variant alleles from rs10455872 and rs3798220. Allelic P is a test of the per-allele linear trend. Genotypic P is a test of difference between 0 vs 1 vs 2.
Results
Baseline Characteristics and Lipid Associations
Associations of LPA With Prevalent Vascular Disease
Association of LPA With Incident Vascular Events
*P adjusted for prior coronary heart disease, stroke, and peripheral vascular disease. Table 4) .
Discussion
The present study demonstrated that LPA variants were significantly associated with some, but not all atherothrombotic vascular disease outcomes. The LPA genotype score, which had previously been shown to explain more than half of the genetic variation in plasma levels of Lp(a), 1 was associated with a 20% higher risk per additional variant allele for both prevalent and incident coronary disease and peripheral vascular disease. In contrast, there was no significant association of the LPA genotype score with prevalent or incident ischemic stroke. The present study (1326 prevalent and 507 incident ischemic stroke cases) and a meta-analysis carried out by Wang et al 6 involving 3550 stroke cases have reported no significant association of stroke with LPA variants. In contrast, the Women's Health Study 17 (123 ischemic stroke cases) suggested a positive association of rs3798220 with stroke; albeit, it failed to detect a significant association with myocardial infarction (fully adjusted Pϭ0.11). In addition, a meta-analysis of observational studies involving 1684 ischemic stroke cases reported that Lp(a) levels were similarly associated with coronary disease and stroke. 5 The apparent discrepancy between evidence in the HPS (and other genetic studies 6 ) and results linking LPA and plasma levels of Lp(a) with risk of ischemic stroke may be partly due to confounding by incomplete control for prior coronary disease or by concomitant nonfatal coronary events. Consequently, the association between Lp(a) level and stroke in the meta-analysis of obser- vational studies may have been inflated by the association of Lp(a) with coronary disease. To minimize such biases when analyzing the HPS, individuals with prior coronary disease were excluded from analyses of prevalent stroke, and the associations with incident stroke were adjusted for prior coronary disease. The magnitude of the effect of this confounding is indicated by sensitivity analysis of the HPS, which showed that inclusion of individuals with prior coronary disease increased the association of LPA score with prevalent stroke from 1.03 (Pϭ0.67) to 1.09 (Pϭ0.14). Thus, differences in ascertainment of cases, population differences (eg, prior disease), the effect of chance, and competing risks of coronary disease and stroke may explain the discrepant results of Lp(a) levels, LPA variants, and stroke in different studies. Differing effects of LPA variants on individual stroke subtypes also may contribute to inconsistencies between the results of the HPS and some previous studies. 18 However, because the HPS is unable to assess the effects of LPA on different stroke subtypes, further studies are required to examine potentially variable effects of LPA on strokes of differing etiology. The HPS is a secondary prevention population of older individuals (mean age, 64 years) and, hence, has higher incident event rates than the general population. The impact of the survivor bias in such populations with prevalent disease is not known. Although the observed effect sizes for LPA and coronary disease in the HPS are weaker than those reported in the PROCARDIS study, 1 PROCARDIS was a genetically enriched study of early-onset coronary disease. The higher event rates observed in the HPS compared with the general population provides additional statistical power and when examining the associations with incident disease, allows us to explore the impact of the LPA variants on secondary events (ie, events in those with a history of vascular disease). Indeed, the comparability of the effects of the LPA variants for prevalent and incident vascular disease is of considerable interest.
The lack of availability of Lp(a) levels in the HPS is a potential limitation of the study because it does not allow us to assess the variability of measured values within this secondary prevention population. Although Lp(a) levels were not measured, the 2 SNPs contributing to the LPA genotype score have been strongly and consistently associated with Lp(a) levels in 4 independent studies involving 3422 individuals, 1 and a further study 17 has shown rs3798220 to be strongly associated with Lp(a) levels in Ͼ25 000 individuals. Although the LPA variants studied encode higher plasma levels of Lp(a), the mechanism by which elevated levels of Lp(a) cause atherothrombotic vascular disease, are not fully understood, it may involve LDL-C, 19 the inhibition of the expression of tissue factor, 20 the inhibition of conversion of plasminogen to plasmin, 21 or the carriage of proinflammatory oxidized phospholipids. 22 Lp(a) is believed to exert both proatherogenic and prothrombotic effects, some of which depend on apo(a) and others that depend on apoB. It is unclear whether this dependency of Lp(a) on apoB is relevant to the lack of association with ischemic stroke. In a metaanalysis of prospective studies involving 12 000 stroke deaths, there was only a weak positive association between cholesterol and ischemic stroke mortality in middle-age and little or no association at older ages. 23 In contrast, randomized trials have shown that reducing LDL-C with statin therapy produces comparable reductions in the risk of coronary disease and of ischemic stroke. 23, 24 Consequently, the lack of evidence of an association of LPA and stroke in the present study does not exclude the possibility that lowering Lp(a) would have beneficial effects on the risk of ischemic stroke. A large-scale randomized trial of niacin, which reduces Lp(a) levels, is in progress and may help to address the uncertainty of the effects of lowering Lp(a) levels on vascular outcomes, including stroke. 25 Further studies are required to assess the relevance of LPA variants with other vascular disease outcomes, including venous thromboembolism. Specificity of the effects of LPA variants for different atherosclerotic and thrombotic diseases also may be informative for our understanding of the pathophysiology of Lp(a).
In conclusion, we have demonstrated that the associations of LPA variants with coronary disease and peripheral vascular disease are of comparable strength, but there appears to be little or no association of LPA with ischemic stroke in the HPS. These findings suggest that Lp(a) may have effects on atherothrombotic vascular disease that are only relevant at specific sites.
